Single-arm phase 2 study | Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma

Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Futibatinib in Previously Treated Patients With Advanced FGFR2-Rearranged Intrahepatic Cholangiocarcinoma – ASCO Post

Commentary on Twitter

FGFR2 fusions or rearrangements occur in up to 14% of patients with intrahepatic cholangiocarcinoma. In a study, futibatinib, an FGFR inhibitor, induced responses (median, 9.7 months) in 42% of patients. https://t.co/FAXE2AnQ90 pic.twitter.com/9Fn9KxZxeg

— NEJM (@NEJM) January 19, 2023